Identification of key miRNA signature and pathways involved in multiple myeloma by integrated bioinformatics analysis

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–1060.
   PubMed Web of Science ®Google Scholar
• Pawlyn C, Morgan G. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17(9):543–556.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working group. J Clin Oncol: Official J Am Soc Clin Oncol. 2015;33(26):2863–2869.
   PubMed Web of Science ®Google Scholar
• Cejalvo M, de la Rubia J. Clinical treatment of newly diagnosed multiple myeloma. Expert Rev Hematol. 2015;8(5):595–611.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working group. Blood. 2016;127(24):2955–2962.
   PubMed Web of Science ®Google Scholar
• Kuiper R, Broyl A, de Knegt Y, et al. A gene expression signature for high-risk multiple myeloma. Leukemia. 2012;26(11):2406–2413.
   PubMed Web of Science ®Google Scholar
• Chng W, Chung T, Kumar S, et al. Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia. 2016;30(5):1071–1078.
   PubMed Web of Science ®Google Scholar
• Mitra A, Harding T, Mukherjee U, et al. A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma. Blood Cancer J. 2017;7(6):e581.
   PubMedGoogle Scholar
• Zamani-Ahmadmahmudi M, Nassiri S, Soltaninezhad F. Development of an RNA sequencing-based prognostic gene signature in multiple myeloma. Br J Haematol. 2021;192(2):310–321.
   PubMed Web of Science ®Google Scholar
• Liu X, Yin X, Meng X, et al. Development and validation of a 9-gene prognostic signature in patients with multiple myeloma. Front Oncol. 2018;8:615.
   PubMed Web of Science ®Google Scholar
• Laganà A, Perumal D, Melnekoff D, et al. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. Leukemia. 2018;32(1):120–130.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yu H, Yoo S, et al. A network analysis of multiple myeloma related gene signatures. Cancers (Basel). 2019;11(10):1452, doi: https://doi.org/10.3390/cancers11101452.
   Web of Science ®Google Scholar
• Kaikkonen M, Lam M, Glass C. Non-coding RNAs as regulators of gene expression and epigenetics. Cardiovasc Res. 2011;90(3):430–440.
   PubMed Web of Science ®Google Scholar
• Ling H, Fabbri M, Calin G. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12(11):847–865.
   PubMed Web of Science ®Google Scholar
• Lionetti M, Biasiolo M, Agnelli L, et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood. 2009;114(25):e20–e26.
   PubMed Web of Science ®Google Scholar
• Gutiérrez N, Sarasquete M, Misiewicz-Krzeminska I, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia. 2010;24(3):629–637.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhou L, Shi M, et al. Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN1 expression. Oncol Lett. 2018;15(1):1287–1296.
   PubMed Web of Science ®Google Scholar
• Yoshizawa S, Ohyashiki J, Ohyashiki M, et al. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J. 2012;2(1):e53.
   PubMedGoogle Scholar
• Umezu T, Tadokoro H, Azuma K, et al. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014;124(25):3748–3757.
   PubMed Web of Science ®Google Scholar
• Gupta N, Kumar R, Seth T, et al. Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signalling. RNA Biol. 2020;17(1):98–111.
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu H, Fang C, et al. Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma. Cancer Res. 2020;80(10):2031–2044.
   PubMed Web of Science ®Google Scholar
• Robak P, Dróżdż I, Jarych D, et al. The value of serum MicroRNA expression signature in predicting refractoriness to bortezomib-based therapy in multiple myeloma patients. Cancers (Basel). 2020;12(9):2569.
   PubMed Web of Science ®Google Scholar
• Li J, Liu S, Zhou H, et al. Starbase v2.0: decoding miRNA–ceRNA, miRNA–ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:D92–D97.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang L, Han Y, et al. Clusterprofiler: an R package for comparing biological themes among gene clusters. Omics J Integr Biol. 2012;16(5):284–287.
   PubMed Web of Science ®Google Scholar
• Li C, Li X, Miao Y, et al. Subpathwayminer: a software package for flexible identification of pathways. Nucleic Acids Res. 2009;37(19):e131.
   PubMed Web of Science ®Google Scholar
• Cheng F, Kovács I, Barabási A. Network-based prediction of drug combinations. Nat Commun. 2019;10(1):1197.
   PubMed Web of Science ®Google Scholar
• Köhler S, Bauer S, Horn D, et al. Walking the interactome for prioritization of candidate disease genes. Am J Hum Genet. 2008;82(4):949–958.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang M, Wang C. Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. J Clin Lab Anal. 2020;34(6):e23233.
   PubMed Web of Science ®Google Scholar
• Bi C, Chung T, Huang G, et al. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma. Oncotarget. 2015;6(28):26508–26518.
   PubMedGoogle Scholar
• Min D, Ezponda T, Kim M, et al. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC. Leukemia. 2013;27(3):686–694.
   PubMed Web of Science ®Google Scholar
• Toscani D, Bolzoni M, Ferretti M, et al. Role of osteocytes in myeloma bone disease: anti-sclerostin antibody as new therapeutic strategy. Front Immunol. 2018;9:2467.
   PubMed Web of Science ®Google Scholar
• Bolomsky A, Hose D, Schreder M, et al. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma. J Hematol Oncol. 2015;8:10.
   PubMed Web of Science ®Google Scholar
• Seibold M, Stühmer T, Kremer N, et al. RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS. Haematologica. 2020;105(9):2316–2326.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Abe M. TGF-β-related mechanisms of bone destruction in multiple myeloma. Bone. 2011;48(1):129–134.
   PubMed Web of Science ®Google Scholar
• Tsukune Y, Sasaki M, Komatsu N. Reactivation of Hepatitis B virus in patients with multiple myeloma. Cancers (Basel). 2019;11(11):1819.
   Web of Science ®Google Scholar
• Lentzsch S, Chatterjee M, Gries M, et al. PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia. 2004;18(11):1883–1890.
   PubMed Web of Science ®Google Scholar
• Allegra A, Innao V, Polito F, et al. SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma. Clin Biochem. 2021;93:42–49.
   PubMed Web of Science ®Google Scholar
• Lu B, Zhang D, Wang X, et al. Targeting SIRT1 to inhibit the proliferation of multiple myeloma cells. Oncol Lett. 2021;21(4):306.
   PubMed Web of Science ®Google Scholar
• Jang K, Hwang S, Kwon K, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol. 2008;32(10):1523–1531.
   PubMed Web of Science ®Google Scholar
• Sevcikova S, Paszekova H, Besse L, et al. Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(2):288–293.
   PubMed Web of Science ®Google Scholar